Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer

British Journal of Cancer

Volumn 92, Issue 12, 2005, Pages 2134-2139

  Nakamura, K ^a   Yamaguchi, T ^a   Ishihara, T ^a   Kobayashi, A ^a   Tadenuma, H ^a   Sudo, K ^a   Kato, H ^b   Saisho, H ^a  

^a CHIBA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Gemcitabine; Metastatic pancreatic cancer; Phase I study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; GEMCITABINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MALE; NAUSEA; OPEN STUDY; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; PANCREATIC NEOPLASMS; PYRIDINES; TEGAFUR; TREATMENT OUTCOME;

EID: 22044447934     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602644     Document Type: Article

References (31)

1. Berlin JD, Adak S, Vaughn DJ, Flinker D, Blaszkowsky L, Harris JE, Benson I (2000) A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296). Oncology 58: 215-218
2. Berlin JD, Alberti DB, Arzoomanian RZ, Feierabend CA, Simon KJ, Binger KA, Marnocha RM, Wilding G (1998) A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors. Invest New Drugs 16: 325-330
3. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson III AB (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270-3275
4. Bruckner H, Zhou G, Haenel P (1998) Ex vivo ATP tumor testing of gemcitabine for combination chemotherapy and biochemical modulation. Proc Am Assoc Cancer Res 89: 310 (abstr 2116)
5. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413
6. Cascinu S, Silva RR, Barni S, Labianca R, Frontini L, Piazza E, Pancera G, Giordani P, Giuliodori L, Pessi MA, Fusco V, Luporini G, Cellerino R, Catalano G (1999) A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 80: 1595-1598
7. Chollet P, Schoffski P, Weigang-Kohler K, Schellens JH, Cure H, Pavlidis N, Grunwald V, De Boer R, Wanders J, Fumoleau P (2003) Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 39: 1264-1270
8. Evans D, Abbruzzese J, Rich T (1997) Cancer of the pancreas. In Cancer: Principles and Practice of Oncology De Vita VJ, Hellman S, Rosenberg S (eds) pp 1054-1077. Philadelphia: Lippincott
9. Glimelius B, Hoffman K, Sjödén PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7: 593-600
10. Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz-Puente M, Hitt R, Alonso S Cortes-Funes H (1999) Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17: 585-592
11. Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyesy D, Dwivedy S, Russo M, Pazdur R (2003) Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 9: 134-142
12. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B (2001) Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 28: 1381-1390
13. Koizumi W, Kurihara M, Nakano S, Hasegawa K (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58: 191-197
14. Matano E, Tagliaferri P, Libroia A, Damiano V, Fabbrocini A, De Lorenzo S, Bianco AR (2000) Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study. Br J Cancer 82: 1772-1775
15. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K (2004) Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 28: 219-230
16. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T (2000) Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 83: 141-145
17. Okada S, Okusaka T, Ueno H (2002) A phase II and pharmacokinetic trial of S-1 in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 21: 171a
18. Peters GJ, van Groeningen CJ, Laurensse EJ, Pinedo HM (1991) A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 68: 1903-1909
19. Rauchwerger DR, Firby PS, Hedley DW, Moore MJ (2000) Equilibrative- sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 60: 6075 - 6079
20. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris III HA, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD (1996) A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7: 347-353
21. Saeki T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, Morimoto K, Kimura M, Aoyama H, Ota J, Noguchi S, Taguchi T (2004) A phase II study of S-1 in patients with metastatic breast cancer - A Japanese trial by the S-1 cooperative study group, Breast Cancer Working Group. Breast Cancer 11: 194-202
22. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 Mtegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720
23. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M (1996a) Antitumor activity of 1 Mtegafur-0.4 M 5-chloro-2,4-dihydroxy-pyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602-2606
24. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996b) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557
25. Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, Furue H, Kurihara M, Ota K, Suga S, Ariyoshi Y, Takai S, Shimoyama T, Toge T, Takashima S, Sugimachi K, Hara Y, Fujita H, Kimura K, Saito T, Tsukagoshi S, Nakao I (1997) Phase I study of S-1. S-1 Study Group. Can To Kagaku Ryoho 24: 2253-2264
26. Takechi T, Fujioka A, Matsushima E, Fukushima M (2002) Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 38: 1271-1277
27. Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, Unemi N, Shirasaka T (1997) Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 39: 205-211
28. Tatsumi K, Fukushima M, Shirasaka T, Fujii S (1987) Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78: 748-755
29. Van den Brande J, Schoffski P, Schellens JH, Roth AD, Duffaud F, Weigang-Kohler K, Reinke F, Wanders J, de Boer RF, Vermerken JB, Fumoleau P (2003) EORTC early clinical studies group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 88: 648-653
30. van Groeningen CJ, Peters GJ, Schornagel JH, Gall H, Noordhuis P, de Vries MJ, Turner SL, Swart MS, Pinedo HM, Hanauske AR, Giaccone G (2000) Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 18: 2772-2779
31. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment (WHO Offset Publication No. 48). Geneva, Switzerland: World Health Organization